Platelet [3H]paroxetine binding in patients with OCD-related disorders

Psychiatry Research

Volumn 89, Issue 3, 1999, Pages 223-228

  Marazziti, Donatella ^a   Dell'Osso, Liliana ^a   Presta, Silvio ^a   Pfanner, Chiara ^a   Rossi, Alessandra ^a   Masala, Irene ^a   Baroni, Stefano ^a   Giannaccini, Gino ^a   Lucacchini, Antonio ^a   Cassano, Giovanni Battista ^a  

^a Dipartmento di Biologia   (Italy)

Author keywords

3H Paroxetine binding; Obsessive compulsive disorder (OCD); OCD spectrum disorders; Platelets; Serotonin; Serotonin transporter

Indexed keywords

FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; PAROXETINE; RADIOLIGAND; SEROTONIN TRANSPORTER; TRITIUM; CARRIER PROTEIN; DRUG RECEPTOR; MEMBRANE PROTEIN; NERVE PROTEIN; PAROXETINE RECEPTOR; SLC6A4 PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; BINDING SITE; BODY DYSMORPHIC DISORDER; CLINICAL PATHWAY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; FEMALE; GILLES DE LA TOURETTE SYNDROME; HUMAN; HUMAN CELL; KLEPTOMANIA; MALE; OBSESSION; OUTPATIENT; PERSONALITY DISORDER; PRESYNAPTIC MEMBRANE; PRIORITY JOURNAL; SCHOOL CHILD; SEROTONINERGIC SYSTEM; THROMBOCYTE; TRICHOTILLOMANIA; METABOLISM; OBSESSIVE COMPULSIVE DISORDER; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADOLESCENT; ADULT; BLOOD PLATELETS; CARRIER PROTEINS; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; OBSESSIVE-COMPULSIVE DISORDER; PAROXETINE; RECEPTORS, DRUG; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 0033233296     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1781(99)00102-X     Document Type: Article

References (34)

1. Bastani B., Arora R.C., Meltzer H.Y. Serotonin uptake and imipramine binding in the blood platelets of obsessive-compulsive disorder patients. Biological Psychiatry. 30:1991;131-139.
2. Black D.W., Kelly M., Myers C., Noyes R. Jr. Tritiated imipramine binding in obsessive-compulsive volunteers and psychiatrically normal controls. Biological Psychiatry. 27:1990;319-327.
3. Coccaro E.F., Kavoussi R.J., Sheline Y.I., Lish J.D., Csernansky J.C. Impulsive aggression in personality disorder correlates with tritiated paroxetine binding in the platelets. Archives of General Psychiatry. 53:1996;531-536.
4. Fineberg N. Refining treatment approaches in obsessive-compulsive disorder. Journal of Clinical Psychopharmacology. 11(Suppl. 5):1996;13-22.
5. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorders - Patient Edition (SCID-I/P, Version 2.0, 4/97 revision). 1997;Biometrics Research Department, New York State Psychiatric Institute, New York.
6. Goodman W.K., Price L.H., Rasmussen S.A. The Yale Brown Obsessive-Compulsive Scale I: development, use and reliability. Archives of General Psychiatry. 46:1986;1006-1011.
7. Greist J.H., Jefferson J.W., Kobak K.H., Katzenlick D.J., Serlin R.C. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. Archives of General Psychiatry. 52:1995;53-60.
8. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry. 6:1960;189-192.
9. Hollander E. Obsessive-Compulsive Related Disorders. 1993;American Psychiatric Press, Washington, DC.
10. Hollander E., Wong C.M. Body dysmorphic disorder, pathological gambling and sexual compulsions. Journal of Clinical Psychiatry. 56(Suppl. 4):1995;7-12.
11. Hollander E., DeCaria C.M., Mari E., Wong C.M., Mosovich S., Grossman R., Begaz T. Short-term single-blind fluvoxamine treatment of pathological gambling. American Journal of Psychiatry. 155:1998;1781-1783.
12. Insel T.R., Mueller E.A., Alterman I., Linnoila M., Murphy D.L. Obsessive-compulsive disorder and serotonin: is there a connection? Biological Psychiatry. 20:1985;1174-1188.
13. Jenike M.A. Illnesses related to obsessive-compulsive disorder. Jenike M.A., Baer L.B., Minichiello W.E. Obsessive-Compulsive Disorders: Theory and Management. 1990;39-60 Year Book Medical, Chicago.
14. Karno M., Golding J.M., Sorenson S.B. The epidemiology of obsessive-compulsive disorder in five US Communities. Archives of General Psychiatry. 45:1988;1094-1099.
15. Lesch K.P., Bengel D., Heils A., Sabol S.Z., Greenberg B.D., Petri S., Benjamin J., Muller C.R., Hamer D.H., Murphy D.L. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science. 274:1996;1527-1531.
16. 3H-paroxetine binding in obsessive-compulsive disorder. Human Psychopharmacology. 10:1995;141-146.
17. Marazziti D., Hollander E., Lensi P., Ravagli S., Cassano G.B. Peripheral markers of serotonin and dopamine function in obsessive-compulsive disorder. Psychiatry Research. 42:1992;41-51.
18. 3H-paroxetine binding in obsessive-compulsive patients. Neuropsychobiology. 34:1996;184-187.
19. Marazziti, D., Masala, I., Rossi, A., Hollander, E., Presta, S., Giannaccini, G., Mazzoni, M.R., Dell'Osso, L., Lucacchini, A., Cassano, G.B. Increased inhibitory activity of protein kinase C on the serotonin transporter in OCD. Neuropsychobiology (in press).
20. 3H-imipramine to protease-sensitive and protease-resistant sites. Journal of Neurochemistry. 4:1985;705-711.
21. Mazzanti C., Lappalainen J., Long J.C., Bengel D., Naukkarinen H., Eggert M., Virkunnen M., Linnoila M., Goldman D. Role of the serotonin transporter promoter polymorphism in anxiety-related traits. Archives of General of Psychiatry. 55:1998;936-940.
22. McPherson, G.A., 1995. Kinetic, EBDA, LIGAND, Lowry: a collection of radioligand analysis programs. Biosoft, Cambridge, UK.
23. Montgomery S.A. Pharmacological treatment of obsessive-compulsive disorder. Hollander E., Zohar J., Marazziti D., Olivier B. Current Insights in Obsessive-Compulsive Disorder. 1994;123-137 Wiley & Sons, Chichester, UK.
24. Nelson E.C., Sheline Y.I., Bardgett M.E., Jackson J.L., Csernansky J.G. Platelet paroxetine binding in major depressive disorder with and without comorbid obsessive-compulsive disorder. Psychiatry Research. 58:1995;117-125.
25. Nie N.H., Hull C.H., Steinbrenner K., Bent D.H. Statistical Package for the Social Sciences (SPSS). 2nd ed. 1975;McGraw-Hill Company, New York.
26. Peterson G.L. A simplification of the protein assay method that is more generally applicable. Analytical Biochemistry. 83:1977;346-356.
27. Phillips K.A., Hollander E., Rasmussen S.A., Aronowitz B.A., DeCaria C.M., Goodman W.K. A severity rating scale for body dysmorphic disorder: development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale. Psychopharmacology Bulletin. 33(1):1997;17-22.
28. Piccinelli M., Pini S., Bellantuono C., Wilkinson C. Efficacy of drug treatment in obsessive-compulsive disorder. British Journal of Psychiatry. 166:1995;424-443.
29. Rasmussen S.A., Tsuang M.T. Clinical characteristics and family history in DSM-III obsessive-compulsive disorder. American Journal of Psychiatry. 143:1986;317-322.
30. Robins L.N., Helzer J.E., Weissman M.M. Lifetime prevalence of specific psychiatric disorders in three sites. Archives of General Psychiatry. 41:1984;949-958.
31. Sallee F.R., Richman H., Beach K., Sethuram G., Nesbitt L. Platelet serotonin transporter in children and adolescents with obsessive-compulsive disorder or Tourette's syndrome. Journal of the American Academy of Child and Adolescent Psychiatry. 35:1996;1647-1656.
32. Simeon D., Stein D.J., Hollander E. Treatment of depersonalization disorder with clomipramine. Biological Psychiatry. 44:1998;302-303.
33. Vitiello B., Shimon H., Behar L., Stoff D., Bridger W.H., Friedman E. Platelet imipramine binding and serotonin uptake in obsessive-compulsive patients. Acta Psychiatrica Scandinavica. 84:1991;29-32.
34. Weizman R., Carmi M., Hermesh H., Shahar A., Apter A., Tyano S., Rehavi M. High-affinity imipramine binding and serotonin uptake in platelets of eight adolescent and ten adult obsessive-compulsive patients. American Journal of Psychiatry. 143:1986;335-339.